Celecoxib reduces the effects of acute and chronic UVB exposure in mice treated with therapeutically relevant immunosuppressive drugs

摘要: Solid organ transplant recipients have a greatly increased risk for the development of non-melanoma skin cancers. We previously shown in our mouse model that sirolimus given combination with cyclosporine A resulted fewer and smaller tumors than alone. In current study, we tested hypothesis an anti-inflammatory agent celecoxib applied topically after UVB exposure would further reduce induced cancer mice treated sirolimus. The effect treatment on acute inflammation, initiation/promotion tumor was examined through set four experiments. Delayed onset observed both Reduced size number compared to vehicle when CX administered concurrently cessation treatments, respectively. Prostaglandin E2 confirmed be significantly reduced dorsal immunosuppressants, 13 weeks, suggesting reduction inflammatory response could mechanism by which tumorigenesis. Furthermore, topical following dermal neutrophil activity vehicle. all these experiments, unirradiated were utilized as controls. conclusion, data suggest even presence sirolimus, can result size; properties may beneficial therapeutic solid recipients.